Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00499408 · ClinicalTrials.gov registry record · Phase 2

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

A Phase 2 study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target

NCT00499408: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.

NCT00499408 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00499408, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target

Study Summary

RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment. PURPOSE: This phase II trial is studying how well giving vitamin D together with soy supplements works in treating patients with recurrent prostate cancer.

Interventions

  • DIETARY_SUPPLEMENT Vitamin D
  • DIETARY_SUPPLEMENT soy

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2007-04
Est. Completion 2012-12
Phase Phase 2
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT00499408 record still lists

NCT00499408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).

The record links to 0 conditions, and to 2 interventions - of which Vitamin D is the first listed.

NCT00499408 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00499408 about?

NCT00499408 is a clinical study titled "Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer". RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment. PURPOSE: This phase II trial is studying how well giving vitamin D together with soy supplements works in...

What is the current status of trial NCT00499408?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-04. Estimated completion is 2012-12.

What interventions are being tested in trial NCT00499408?

The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), soy (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00499408?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00499408's enrollment target sits among peer trials

26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00499408, the US trial registry maintained by the National Library of Medicine. NCT00499408 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.